Black Diamond Therapeutics Inc (NASDAQ: BDTX) is -45.11% lower on its value in year-to-date trading and has touched a low of $1.20 and a high of $6.75 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BDTX stock was last observed hovering at around $2.6 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $2.58, the stock is 5.76% and 22.05% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.47 million and changing -0.77% at the moment leaves the stock 5.93% off its SMA200. BDTX registered 20.56% gain for a year compared to 6-month gain of 20.00%.
The stock witnessed a 3.20% loss in the last 1 month and extending the period to 3 months gives it a 63.29%, and is 4.88% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.49% over the week and 7.35% over the month.
Black Diamond Therapeutics Inc (BDTX) has around 24 employees, a market worth around $146.70M and $70.00M in sales. Current P/E ratio is 41.82. Profit margin for the company is 7.27%. Distance from 52-week low is 115.90% and -61.78% from its 52-week high. The company has generated returns on investments over the last 12 months (3.19%).
The EPS is expected to grow by 117.72% this year
The shares outstanding are 56.68M, and float is at 43.28M with Short Float at 15.79%.
The top institutional shareholder in the company is T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with over 10.66 million shares valued at $49.67 million. The investor’s holdings represent 20.5751 of the BDTX Shares outstanding. As of 2024-06-30, the second largest holder is BELLEVUE GROUP AG with 8.52 million shares valued at $39.69 million to account for 16.4409 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 4.45 million shares representing 8.5869 and valued at over $20.73 million, while BLACKROCK INC. holds 6.2096 of the shares totaling 3.22 million with a market value of $14.99 million.
Black Diamond Therapeutics Inc (BDTX) Insider Activity
The most recent transaction is an insider sale by BIOTECH GROWTH N V, the company’s 10% Owner. SEC filings show that BIOTECH GROWTH N V sold 5,784,292 shares of the company’s common stock on Mar 19 ’25 at a price of $2.07 per share for a total of $12.0 million. Following the sale, the insider now owns 2.73 million shares.
Black Diamond Therapeutics Inc disclosed in a document filed with the SEC on Aug 28 ’24 that Versant Venture Capital VI, L. (10% Owner) sold a total of 221,600 shares of the company’s common stock. The trade occurred on Aug 28 ’24 and was made at $6.32 per share for $1.4 million. Following the transaction, the insider now directly holds 3.73 million shares of the BDTX stock.
